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Results Six patients (12.2 %) in the pregabalin group and 
22 patients (46.8 %) in the control group underwent spinal 
surgery during the first year of treatment (P = 0.0035). The 
period in which patients decided to undergo spinal surgery 
was significantly delayed in the pregabalin group compared 
with the control group in those for whom spinal surgery 
was necessary (P = 0.0128).
Conclusions Nonsteroidal anti-inflammatory drug and 
pregabalin combination therapy may result in a lower inci-
dence of spinal surgery during the first year of treatment or 
a delayed period before undergoing spinal surgery if nec-
essary compared with nonsteroidal anti-inflammatory drug 
monotherapy in patients with leg symptoms caused by lum-
bar spinal stenosis.
Introduction
Lumbar spinal stenosis (LSS) is the most common reason 
for spinal surgery in patients older than 65 years [1, 2]. The 
symptoms of LSS may occur as a result of neurovascular 
mechanisms [3–5], such as reduced arterial flow in the 
cauda equina, venous congestion, increased epidural pres-
sure, nerve root infiltration, and direct compression in the 
central canal or lateral recess [6]. The characteristic symp-
tom of LSS is neurogenic intermittent claudication (NIC) 
[7, 8], but additional symptoms can include radicular pain 
down the leg, and numbness and motor weakness in the 
legs. If conservative treatments fail to improve the symp-
toms after 3–6 months, decompressive surgery is usually 
considered. However, patients aged above 65 years with 
symptomatic LSS have increased risks of complications 
in spinal surgery because of their previous illnesses and 
common comorbidities such as cardiovascular disease and 
chronic lung disease.
Abstract 
Background Pregabalin is a well-accepted treatment 
option for patients with neuropathic pain. However, the 
therapeutic efficacy of pregabalin for reducing the inci-
dence of spinal surgery to treat leg symptoms in patients 
with lumbar spinal stenosis remains unknown. The purpose 
of this study was to analyze the therapeutic efficacy of pre-
gabalin for reducing the incidence of spinal surgery for leg 
symptoms in patients with lumbar spinal stenosis during 
the first year of treatment.
Methods Consecutive patients diagnosed with lumbar 
spinal stenosis at our hospital from January to June 2009 
were treated with nonsteroidal anti-inflammatory drug 
monotherapy and formed the control group (n = 47; 22 
males, 25 females). Patients diagnosed with lumbar spinal 
stenosis at our hospital between August 2010 and October 
2011 were treated with a nonsteroidal anti-inflammatory 
drug and pregabalin combination therapy and formed the 
pregabalin group (n = 49; 27 males, 22 females). The 
proportions of patients who underwent spinal surgery 
during the first year of treatment were assessed and com-
pared between the two groups using the Mann-Whitney U 
test. In addition, the periods in which patients decided to 
undergo spinal surgery were compared using the Kaplan-
Meier method.
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Pregabalin is a well-accepted treatment option for neu-
ropathic pain owing to its analgesic, anxiolytic, and antiepi-
leptic properties [9–11]. It is a structural analog of gamma-
aminobutyric acid that potently and selectively binds to 
the alpha2-delta subunit of voltage-dependent calcium 
channels. Potent binding at these sites reduces the calcium 
influx at nerve terminals, thereby reducing the release of 
several excitatory neurotransmitters, including glutamate, 
noradrenaline, and substance P, and accounting for the 
therapeutic effects. Nonsteroidal anti-inflammatory drug 
(NSAID) and pregabalin combination therapy is one con-
servative treatment for LSS. However, it remains unknown 
whether NSAID and pregabalin combination therapy can 
have beneficial effects over a long period of time. The pur-
pose of this study was to compare the incidences of spi-
nal surgery during the first year of NSAID monotherapy 
and the first year of NSAID and pregabalin combination 
therapy.
Materials and methods
We performed a retrospective cohort study of patients 
diagnosed with LSS at our institute between January 2009 
and October 2011. The study received institutional review 
board approval from our hospital. Consecutive patients 
newly diagnosed with LSS from January to June 2009 were 
treated with NSAID monotherapy and formed the control 
group. Patients newly diagnosed with LSS between August 
2010 and October 2011 were treated with NSAID and pre-
gabalin combination therapy and formed the pregabalin 
group. The patients in the control group were not given pre-
gabalin because the practice of prescribing pregabalin for 
patients with neuropathic pain was not adopted in Japan 
until August 2010. Three spinal surgeons diagnosed the 
patients with LSS, based not only on imaging findings of 
lumbar spinal canal stenosis, but also on subjective symp-
toms and/or neurological findings. Therefore, all patients 
had subjective symptoms and neurological findings caused 
by LSS, and imaging findings of lumbar spinal canal 
stenosis.
An independent radiologist assessed the magnetic 
resonance images obtained for each patient at the time of 
diagnosis for evidence of lumbar canal stenosis, which 
included central stenosis, lateral recess stenosis, and 
foraminal stenosis. The ankle brachial pressure index 
(ABI) was also checked in all patients to distinguish 
NIC from vascular intermittent claudication (ABI: <0.9). 
When providing informed consent, the patients were 
informed that surgical treatment was superior to con-
servative management of LSS [14–17] and that the ther-
apeutic approach at our hospital was to use conservative 
management, reserving surgery and other therapies, such 
as epidural block or root block, for cases in which the 
therapeutic effect is insufficient during the first 3 months 
of conservative management. In the first 3 months of the 
study, patients who felt that the medical treatment was 
insufficient were able to request spinal surgical treatment. 
No patients reported wanting surgical or other therapies 
during this time period.
The inclusion criteria for all subjects were: (1) diagno-
sis of lumbar spondylosis or degenerative spondylolisthesis 
with LSS; (2) pain and/or numbness in the lumbar derma-
tomal distribution; (3) motor or sensory neurological signs 
(hypoesthesia, hyperesthesia, allodynia, or dysesthesia) in 
the affected dermatomes; (4) cognitive capability to com-
plete our enquiries; (5) no previous history of treatment for 
symptoms of LSS; and (6) NIC caused by LSS. The exclu-
sion criteria for all subjects were: (1) diagnosis of lumbar 
degenerative disease without LSS; (2) predominantly axial 
spinal pain; (3) significant motor deficits and/or bowel or 
bladder dysfunction; (4) rheumatoid arthritis; (5) known 
renal insufficiency, diabetes, congestive heart failure, car-
diac conduction abnormalities, or thrombocytopenia; (6) 
known peripheral neuropathy; (7) history of spinal surgery; 
(8) history of workmen’s compensation or disability issues; 
(9) chronic depression and use of antidepressant medica-
tion; (10) renal dysfunction (creatinine clearance: <60 ml/
min); (11) absolute requirement for surgical treatment 
because of tertiary paralysis or bladder dysfunction; and 
(12) ABI of <0.9. Additional exclusion criteria for the pre-
gabalin group were: (1) previous history of gabapentin use 
or failure to respond to gabapentin use; (2) history of angi-
oedema with pregabalin use; (3) known hypersensitivity to 
pregabalin use (hives, blisters, rash, dyspnea, or wheezing); 
and (4) need to drive a motor vehicle.
A total of 60 consecutive patients (30 male, 30 female) 
who were newly diagnosed with LSS at our hospital from 
January to June 2009 satisfied the inclusion criteria, did not 
meet the exclusion criteria, and provided informed consent 
for the treatment (Fig. 1). These patients were prescribed 
an NSAID, in the form of loxoprofen sodium hydrate or 
celecoxib. Within the first year after the start of medical 
treatment, eight patients were diagnosed with another dis-
ease, two patients died, one of a heart attack and the other 
of a malignant tumor, and three patients stopped the medi-
cal treatment and withdrew from all treatment. The remain-
ing 47 patients (71.7 %; 22 males, 25 females) formed the 
control group. Thirty-one of these patients received loxo-
profen sodium hydrate and 16 received celecoxib.
Among 126 patients who were newly diagnosed with 
LSS at our hospital from August 2010 to October 2011, 
64 (30 male, 34 female) satisfied the inclusion crite-
ria, did not meet the exclusion criteria and provided 
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informed consent for the treatment. These patients were 
prescribed an NSAID, in the form of loxoprofen sodium 
hydrate or celecoxib, for the first 2 weeks, and prega-
balin was added to the treatment regimen from the third 
week onward (Fig. 1). Pregabalin was started at a dose of 
25 or 50 mg/day (Fig. 1). Patients with a body weight of 
≥50 kg received a dose of 50 mg/day, while those with 
a body weight of <50 kg received a dose of 25 mg/day. 
If the selected dose did not produce sufficient pain relief 
within the first week, it was increased to 150 mg/day, and 
if that dose did not produce sufficient pain relief within 
the following week, it was further increased to 300 mg/
day (Fig. 1). Pregabalin therapy was only started after 
renal function had been assessed to ensure that the cre-
atinine clearance was >60 ml/min. Within the first year 
after the start of medical treatment, eight patients were 
diagnosed with another disease, one patient died because 
of a malignant tumor, and four patients stopped the medi-
cal treatment and withdrew from all treatment. Two of the 
64 patients dropped out after experiencing side effects of 
pregabalin during treatment. The reported side effects of 
pregabalin were staggering, dizziness, and drowsiness. 
The remaining 49 patients (79 %; 27 males, 22 females) 
formed the pregabalin group. Thirty-one of these patients 
received loxoprofen sodium hydrate and 18 received 
celecoxib.
All patients were observed for the appearance of heart 
disease and intestinal hemorrhage, as well as disorders of 
internal organs such as the liver and kidney, while receiving 
NSAID treatment. All patients took a proton pump inhibitor 
once daily to prevent gastritis and/or gastroesophageal reflux 
disease. All patients were monitored throughout the year to 
determine whether they required spinal surgery. Absolute 
indications for spinal surgery were rarefied paralysis, dys-
function of bladder and bowel, or NIC within 10 min.
The numerical rating scale (NRS) score and Roland-
Morris disability questionnaire (RDQ) score were used to 
compare the severity of subjective symptoms and quality of 
life associated with low back pain between the two groups 
before treatment. The NRS was used by the patients them-
selves for self-evaluation of their leg pain and/or numbness. 
The NRS and RDQ scores were examined before and after 
3 months of treatment.
The primary outcome was the need for spinal surgery 
within 1 year after the start of medical treatment. We 
compared the demographic and clinical characteristics 
of the patients, the NRS and RDQ scores before and after 
3 months of treatment, the distances causing NIC (<100 m, 
100–500 m, or >500 m) before and after 3 months of treat-
ment, and the proportions of patients who underwent spi-
nal surgery during this time period between the two groups 
using the Mann-Whitney U test. In addition, the periods 
in which the patients decided to undergo spinal surgery, if 
necessary, were compared between the two groups using 
the Kaplan-Meier method. Values of P < 0.05 were consid-
ered to indicate statistical significance. All statistical analy-
ses were performed using StatView 5.0 statistical software 
(SAS Inc., Cary, NC).
Results
The demographic and clinical characteristics of the patients 
are shown in Table 1. The age, sex distribution, physical 
status, smoking status, proportion of patients performing 
manual labor, and proportion of patients with professional 
Fig. 1  Flowchart of dosages 
in the pregabalin and control 
groups. NSAID Nonsteroidal 
anti-inflammatory drug (n=64)
NSAID only (2 weeks) (n=64)
NSAID + pregabalin 25 or 50 mg/day (1 week)
Effect(-) (n=48)
NSAID + pregabalin 150 mg/day (1 week)
Effect(+) (n=14)
NSAID + pregabalin 300 mg/day 
NSAID only
Keep
Effect(+) (n=42)
Keep 
Control groupPregabalin group
Effect(-) (n=6)
Drop out through 
side effects (n=2)
(n=60)
896 N. Takahashi et al.
1 3
qualifications were similar between the pregabalin and con-
trol groups. In both groups, the majority of patients were 
aged between 60 and 70 years. The mean duration of pain, 
affected spinal level, number of spinal stenosis levels on 
magnetic resonance images, cause of LSS, and NRS and 
RDQ scores before treatment (Tables 2 and 3) were also 
similar between the pregabalin and control groups. How-
ever, the NRS (P < 0.0001) and RDQ (P = 0.0001) scores 
after 3 months of treatment were significantly lower in the 
pregabalin group than in the control group (Tables 2 and 3). 
The distances causing NIC (<100 m, 100–500 m, or >500 
m) before and after 3 months of treatment were similar 
between the pregabalin and control groups (Table 4).   
No patients underwent spinal surgery during the first 
3 months of medical treatment. Of the 49 patients in the 
pregabalin group, 4 (2 males, 2 females) recovered within 
the first year of medical treatment, 6 (2 males, 4 females) 
required spinal surgery within the first year of medical 
treatment, and 39 (23 males, 16 females) continued the 
medical treatment after 1 year. Of the 47 patients in the 
control group, 4 (3 males, 1 female) recovered after the 
first year of medical treatment, 22 (9 males, 13 females) 
required spinal surgery treatment within the first year of 
medical treatment, and 21 (10 males, 11 females) con-
tinued the medical treatment after 1 year. Thus, 6 of 49 
patients (12.2 %) in the pregabalin group and 22 of 47 
patients (46.8 %) in the control group required spinal sur-
gery treatment between 3 months and 1 year after the start 
Table 1  Demographic and clinical characteristics of the patients
Data are shown as mean ± standard error or n (%)
a
 Mann-Whitney U test
Pregabalin 
group  
(n = 49)
Control  
group  
(n = 47)
P value
Age (years) 68.1 ± 1.56 68.5 ± 1.48 0.983a
Sex 0.484a
Male 27 (55.1) 22 (46.8)
Female 22 (44.9) 25 (53.2)
American Society of 
Anesthesiologists physical 
status
0.997a
Level I 25 (51.0) 24 (51.1)
Level II 24 (49.0) 23 (48.9)
Current smoker 4 (8.1) 3 (6.4) 0.881a
Manual laborer 13 (26.5) 12 (25.5) 0.933a
Professional qualification (s) 10 (20.4) 9 (19.1) 0.915a
Duration of pain, months 23.0 ± 6.19 26.4 ± 8.48 0.745a
Affected spinal level 0.889a
L3–L4 5 (10.2) 5 (10.6)
L4–L5 42 (85.7) 39 (83.0)
L5–S1 2 (4.1) 3 (6.4)
Number of spinal stenosis 
levels on magnetic  
resonance images
0.679a
One level 30 (61.2) 31 (66.0)
Two levels 14 (28.6) 12 (25.5)
More than three levels 5 (10.2) 4 (8.5)
Cause of lumbar spinal 
stenosis
0.129a
Lumbar spondylitis 38 (77.6) 29 (61.7)
Degenerative spondylolis-
thesis
11 (22.4) 18 (38.3)
Table 2  NRS scores before and after 3 months of treatment in the 
two groups
Data are shown as mean ± standard error or n (%)
a
 Mann-Whitney U test
Pregabalin group 
(n = 49)
Control group 
(n = 47)
P value
NRS score before 
treatment
7.98 ± 0.25 8.15 ± 0.18 0.717a
NRS score after 
3 months of  
treatment
2.90 ± 0.32 5.91 ± 0.37 <0.0001a
Table 3  RDQ scores before and after 3 months of treatment in the 
two groups
Data are shown as mean ± standard error or n (%)
a
 Mann-Whitney U test
Pregabalin  
group (n = 49)
Control  
group (n = 47)
P value
RDQ score before  
treatment
16.0 ± 0.86 17.0 ± 0.74 0.439a
RDQ score after 
3 months of treatment
6.84 ± 1.26 12.3 ± 1.09 0.0001a
Table 4  Distances causing NIC before and after 3 months of treat-
ment in the two groups
Data are shown as mean ± standard error or n
NRS Numerical rating scale, RDQ Roland-Morris disability question-
naire, NIC neurogenic intermittent claudication
a
 Mann-Whitney U test
Pregabalin  
group 
(n = 49)
Control  
group 
(n = 47)
P value
Distance causing NIC before 
treatment (<100 m/100–500 
m/>500 m)
11/32/6 10/27/10 0.50a
Distance causing NIC after 
3 months of treatment (<100 
m/100–500 m/>500 m)
7/26/16 9/23/15 0.98a
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of medical treatment. These proportions differed signifi-
cantly between the two groups (P = 0.0035). The reasons 
for the spinal surgeries are shown in Table 5. All patients in 
the pregabalin and control groups required spinal surgery 
because of insufficient effects of medical treatment on pain 
reduction. Two of 6 patients (33.3 %) who required surgery 
in the pregabalin group and 10 of 22 patients (45.5 %) who 
required surgery in the control group had aggravation of 
NIC.
The period in which the patients decided to undergo 
spinal surgery was significantly delayed in the pregabalin 
group compared with the control group in those for whom 
spinal surgery was necessary (P = 0.0128) (Table 6).
Discussion
The present study has demonstrated that (1) the NRS and 
RDQ scores before treatment were similar between the pre-
gabalin and control groups, while those after 3 months of 
treatment were significantly lower in the pregabalin group 
than in the control group; (2) the distances causing NIC 
(<100 m, 100–500 m, or >500 m) before and after 3 months 
of treatment were similar between the two groups; and (3) 
the period in which the patients decided to undergo spinal 
surgery was significantly delayed in the pregabalin group 
compared with the control group in those for whom spi-
nal surgery was necessary. These data suggested that the 
incidence of spinal surgery within the first year of medical 
treatment for LSS was significantly lower among patients 
who received NSAID and pregabalin combination therapy 
than among patients who received NSAID monotherapy.
LSS may occur at different levels in the spinal canal and 
may occur at more than one level at the same time. Cen-
tral canal stenosis may compress nerve roots in the cauda 
equina, whereas lateral recess stenosis and foraminal steno-
sis may compress nerve roots while sparing the spine [18, 
19]. Although the lower limb symptoms of LSS are mainly 
attributed to mechanoreceptive compression of nerve root-
lets and the cauda equina, they are also associated with 
inflammation, ischemia, malnutrition, nerve degeneration, 
and nerve injury and consequently have a complicated 
pathophysiology. Therefore, it may be demonstrated that 
the pathomechanisms of lower limb symptoms caused by 
LSS involve nociceptive, inflammatory and/or neuropathic 
pain components. These can result from postural changes 
or persistent compression of the nerve roots and/or cauda 
equina while walking.
Pregabalin is effective at reducing neuropathic pain 
[10–13], but may have few therapeutic effects on inflam-
matory and nociceptive pain. Recent studies using the pain 
DETECT screening questionnaire [20] demonstrated that 
the neuropathic component of pain was more intense than 
the other components of pain in patients with chronic lower 
back pain [20] and that pain, disability, anxiety, and depres-
sion were higher, and quality of life and range of motion 
for passive straight leg raising were lower in patients with 
neuropathic back and leg pain than in patients with nocic-
eptive back and leg pain [20, 21]. These results suggest that 
pregabalin may be effective in LSS patients with radicular 
pain, particularly neuropathic radicular pain. The results of 
Takahashi et al. [12] support this hypothesis, as they found 
that NSAID and pregabalin combination therapy was more 
effective for relief of leg symptoms than NSAID monother-
apy in the chronic phase of LSS over 3 months after the 
first appearance of symptoms and prevented aggravation 
of self-reported symptoms in patients with radicular- and 
mixed-type NIC [12]. Therefore, the results of the present 
study may support the hypothesis that NSAID and prega-
balin combination therapy can reduce the incidence of spi-
nal surgery for patients with leg symptoms caused by LSS. 
This may be beneficial, especially for older patients who 
are at high risk for complications after spinal surgery.
Generally, surgical treatment is superior to conservative 
treatment for LSS irrespective of the degree of affectation 
and whether the patient has spondylolisthesis or NIC [14–
17]. Spinal surgery can be effective despite advanced age, 
multilevel involvement, and comorbidities such as diabetes, 
obesity, chronic coronary disease, and chronic lung disease 
[17, 22–24]. However, these features, especially chronic 
coronary disease and chronic lung disease as well as hos-
pitalization within the year prior to surgery are associated 
with increased complications and mortality [24]. There-
fore, the risks of spinal surgery should be balanced against 
expected improvements for individual patients.
Table 5  Reasons for spinal surgeries in the two groups
NIC Neurogenic intermittent claudication
Pregabalin group 
(n = 6)
Control group 
(n = 22)
Insufficient pain reduction by 
pharmacotherapy
6 22
Aggravation of NIC 2 10
Table 6  Period when the patients decided to have the spinal surgery
Data are shown as mean ± standard error or N (%)
a
 Kaplan-Meier method
Pregabalin 
group  
(n = 6)
Control  
group  
(n = 22)
P value
The period when the patients 
decided to have spinal 
surgery
6.67 ± 1.23 5.59 ± 0.813 0.0128a
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The present study has some limitations that require 
attention. First, the follow-up period was relatively short, 
and future studies are required to evaluate the long-term 
therapeutic efficacy of NSAID and pregabalin combina-
tion therapy. Second, we did not evaluate the therapeu-
tic efficacy of pregabalin alone, and future studies are 
required to evaluate the therapeutic efficacy of pregabalin 
monotherapy. Third, this was a retrospective cohort study 
and therefore open to selection bias. Fourth, two differ-
ent NSAIDs were used. A future study with standardiza-
tion of the NSAID treatment is necessary. A clinical study 
with postlicensure surveillance should be implemented, 
ideally by setting up a database that includes all patients 
seeking treatment for leg symptoms caused by LSS, mini-
mizing losses to follow-up, and using validated methods 
to gather clinically relevant data including demographic 
information, clinical features, common comorbidities, 
conservative and surgical treatments applied to each 
patient, experience and training standards of the care pro-
viders applying each treatment, and each patient’s clinical 
evolution [25].
In conclusion, LSS patients who received NSAID and 
pregabalin combination therapy had a lower incidence of 
spinal surgery for treatment of leg symptoms within the 
first year of therapy and a delayed period before undergo-
ing spinal surgery if necessary compared with LSS patients 
who received NSAID monotherapy. NSAID and pregabalin 
combination therapy may be particularly useful for patients 
of advanced age, who are at high risk of complications 
from spinal surgery.
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